(Q53535031)
Statements
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. (English)
Lachaine J
Laurier C
Langleben A
Vaillant L
1 November 1999
32
2
105-112